Telix Pharmaceuticals Limited (NASDAQ:TLX) Short Interest Down 32.8% in October

Telix Pharmaceuticals Limited (NASDAQ:TLX) was the recipient of a significant decrease in short interest in October. As of October 15th, there was short interest totaling 104,300 shares, a decrease of 32.8% from the September 30th total of 155,200 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 177,500 shares, the short-interest ratio is presently 0.6 days. Based on an average daily volume of 177,500 shares, the short-interest ratio is presently 0.6 days. Currently, 0.0% of the shares of the stock are short sold.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in TLX. Pier Capital LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter valued at $3,037,000. Russell Investments Group Ltd. purchased a new position in Telix Pharmaceuticals in the 2nd quarter worth about $975,000. Jane Street Group LLC purchased a new position in Telix Pharmaceuticals in the 2nd quarter worth about $564,000. ABC Arbitrage SA purchased a new position in Telix Pharmaceuticals in the 1st quarter worth about $451,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in Telix Pharmaceuticals in the 2nd quarter worth about $297,000.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on TLX. JPMorgan Chase & Co. restated a “neutral” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. Wedbush restated an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. HC Wainwright dropped their target price on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, September 10th. Citigroup initiated coverage on shares of Telix Pharmaceuticals in a research report on Thursday, September 18th. They set a “buy” rating and a $22.00 target price for the company. Finally, Canaccord Genuity Group upgraded shares of Telix Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 6th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Telix Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Telix Pharmaceuticals Trading Down 0.7%

TLX stock opened at $10.66 on Friday. Telix Pharmaceuticals has a 52 week low of $8.93 and a 52 week high of $30.36. The company has a fifty day simple moving average of $10.17 and a two-hundred day simple moving average of $13.76.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.